Cat. No. | Product name | CAS No. |
DC3133 |
NVP-BGT226 (BGT226)
Featured
NVP-BGT226 is a novel dual PI3K/mTOR inhibitor with IC50 of 1 nM. |
1245537-68-1 |
DC7303 |
NVP-TAE684
Featured
NVP-TAE684(TAE684) is a highly potent and selective small-molecule ALK inhibitor, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC50 values between 2 and 10 nM. |
761439-42-3 |
DC8700 |
ODM-201(Darolutamide)
Featured
ODM-201 is a potent and full antagonists for human AR (hAR) with IC50 values of 26 nM by transactivation assays in AR-HEK293 cells. |
1297538-32-9 |
DC4110 |
AZD-2281 (Olaparib)
Featured
Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1 and PARP2 with IC50 of 5 nM and 1 nM, respectively. |
763113-22-0 |
DC12281 |
Olutasidenib (FT-2102)
Featured
Olutasidenib is a highly potent, selective inhibitor of mutant Isocitrate dehydrogenase (IDH)1 that could be used in the treatment of acute myeloid leukemia. |
1887014-12-1 |
DC7023 |
Ombrabulin
Featured
Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors. |
181816-48-8 |
DC10054 |
Ombrabulin hydrochloride
Featured
Ombrabulin (AVE8062) hydrochloride is a synthetic derivative of CA-4-P, which inhibits growth in a large number of drug-resistant animal tumors and carcinogen-induced tumors. |
253426-24-3 |
DC10043 |
ONO4059 hydrochloride
Featured
ONO-4059 is a highly selective, orally bioavailable BTK inhibitor with a potency (IC50) of 2.2 nM. |
1439901-97-9 |
DC8358 |
ONO-4059(Tirabrutinib)
Featured
ONO-4059 is a novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase. |
1351636-18-4 |
DC2010 |
Oprozomib (ONX-0912)
Featured
Oprozomib (ONX 0912) selectively inhibits CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. |
935888-69-0 |
DC11203 |
ORIC-101
Featured
ORIC-101 (ORIC101) is a highly potent, selective steroidal glucocorticoid receptor (GR) antagonist (IC50=5.6 nM) with reduced androgen receptor (AR) agonistic activity. |
2222344-98-9 |
DC1006 |
OSI-027
Featured
OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, respectively. |
936890-98-1 |
DC4105 |
Linsitinib(OSI-906)
Featured
OSI-906 (Linsitinib) is a selective inhibitor of IGF-1R and IR with IC50 of 35 nM and 75 nM, respectively. |
867160-71-2 |
DC7219 |
OSI 930
Featured
OSI-930 is a potent inhibitor of Kit, KDR and CSF-1R with IC50 of 80 nM, 9 nM and 15 nM, respectively; also potent to Flt-1, c-Raf and Lck and low activity against PDGFRα/β, Flt-3 and Abl. |
728033-96-3 |
DC8248 |
Ostarine(MK-2286)
Featured
Ostarine(MK-2866; GTX-024)A modulator to human androgen receptor. |
841205-47-8 |
DC7220 |
OSU-03012
Featured
OSU-03012(AR-12) is a potent inhibitor of recombinant PDK-1 with IC50 of 5 μM and 2-fold increase in potency over OSU-02067. |
742112-33-0 |
DC8732 |
OTSSP167
Featured
OTSSP167 is a highly potent MELK inhibitor (IC50 = 0.41 nM) and inhibited the phosphorylation of PSMA1 (proteasome subunit alpha type 1) and DBNL (drebrin-like). |
1431697-89-0 |
DC7475 |
OTSSP167 HCl
Featured
OTSSP167 is a highly potent MELK inhibitor (IC50 = 0.41 nM) and inhibited the phosphorylation of PSMA1 (proteasome subunit alpha type 1) and DBNL (drebrin-like). |
1431698-10-0 |
DC5885 |
Oxaliplatin
Featured
Oxaliplatin is a second generation potent platinum-based anti-neoplastic agent that is believed to form inter- and intrastrand DNA adducts which activate signaling pathways culminating in apoptosis. The development of Oxaliplatin was inspired from the eff |
61825-94-3 |
DC8717 |
PAK4-IN-1(KPT9274)
Featured
PAK4-IN-1 is an inhibitor of p21-activated kinases (PAKs), with IC50 of ≤100 nM in MTT assay. |
1643913-93-2 |
DC8469 |
Palbociclib
Featured
Palbociclib (PD-0332991) is an orally available pyridopyrimidine-derived cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. |
571190-30-2 |
DC5067 |
Palbociclib (PD0332991 HCl)
Featured
Palbociclib is an oral, small molecule cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, now in Phase 3 clinical development for advanced breast cancer. |
827022-32-2 |